For people living with Becker muscular dystrophy — a progressive genetic disease that gradually robs the body of muscle function — the expected trajectory is one of steady decline. There is currently no approved targeted therapy that changes that trajectory. Long-term data presented at the MDA Clinical and Scientific Conference on March 10, 2026, suggests that **sevasemten** could be the drug that finally does.
Edgewise Therapeutics announced results from the MESA open-label extension study showing that patients treated with sevasemten maintained stable functional scores across **3.5 years of follow-up** — a period over which natural history models would have predicted a 5.3-point decline on the North Star Ambulatory Assessment (NSAA) scale used to measure BMD progression.
The actual result: a 0.1-point improvement. Stability, where decline was expected.
**What Becker Muscular Dystrophy Does**
Becker muscular dystrophy (BMD) is a genetic condition caused by mutations in the dystrophin gene — the same gene affected in Duchenne muscular dystrophy, though the mutations are less severe. People with BMD typically retain some functional dystrophin protein, allowing them to walk into adulthood, but the disease steadily erodes muscle mass and strength over decades.
The disease affects predominantly males, estimated at roughly 1 in 18,000. Symptoms typically become apparent in teenage years and progress through adulthood, often leading to loss of ambulation, cardiac complications, and respiratory difficulties. There is currently no approved targeted disease-modifying therapy — only symptom management and supportive care.
**How Sevasemten Works**
Sevasemten (also known as EDG-5506) is a small-molecule inhibitor that modulates fast skeletal muscle troponin — fine-tuning how muscle fibres are activated. In muscles weakened by dystrophin deficiency, this modulation reduces the damaging mechanical stress on already-fragile muscle cells, slowing the progressive damage that drives functional decline.
It is a fundamentally different approach from gene therapy or exon-skipping. Sevasemten doesn't try to fix the underlying genetic problem — it tries to protect what muscle function remains from being lost.
**The Numbers That Matter**
The MESA study data broke down by trial cohort:
- **ARCH trial participants** maintained NSAA scores stable over 3.5 years: +0.1 points, against a natural history prediction of −5.3 points - **CANYON trial participants** showed stability at 2 years: +0.1 points, against a predicted −2.9 points - Patients who received placebo in CANYON and then switched to sevasemten in MESA showed an *upward* trend in NSAA scores in their first year on active treatment — suggesting a genuine treatment effect rather than a statistical artefact
Crucially, sevasemten's long-term safety profile remained favourable across more than three years of continuous exposure — an important finding for a drug patients would potentially take for life.
**On the Path to Potential Approval**
These data are not from the pivotal trial. Edgewise Therapeutics expects top-line results from the fully placebo-controlled GRAND CANYON cohort — the study that would support a regulatory filing — in the fourth quarter of 2026. If those results mirror the MESA extension findings, sevasemten could be on the path to becoming **the first targeted therapy ever approved for Becker muscular dystrophy**.
That would be a landmark moment for the BMD community, and for the broader muscular dystrophy field, which has seen decades of promising research and false dawns. The fact that sevasemten has now been followed for 3.5 years with sustained results and no emerging safety concerns gives the BMD community genuine cause for optimism.
For the thousands of people living with this disease, and their families, 'stable for 3.5 years' is not just a data point. It's what a better life looks like. 💊
*Sources: Edgewise Therapeutics / PR Newswire, MDA Clinical and Scientific Conference 2026, MDA Conference Abstract Library*
